Hjem › Metastatisk kreft › Michigan › Detroit
Kliniske studier for Metastatisk kreft i Detroit, MI
24 studier for Metastatisk kreft søker deltakere på steder i og rundt Detroit (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
RekruttererFase 2/3
- Henry Ford Cancer- Detroit, Detroit
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
RekruttererFase 3
- Research Site, Detroit
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
RekruttererFase 1/2
- Henry Ford Cancer Institute, Detroit
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
RekruttererFase 1
- Karmanos Cancer Institute, Detroit
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RekruttererFase 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
RekruttererFase 3
- Karmanos Cancer Institute, Detroit
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RekruttererFase 3
- Karmanos Cancer Institute, Detroit
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
RekruttererFase 1/2
- Clinical Study Site, Detroit
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
RekruttererFase 2
- Henry Ford Cancer Institute/Henry Ford Health System, Detroit
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
RekruttererFase 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
RekruttererFase 1/2
- Crinetics Study Site, Detroit
A Study of ASP1002 in Adults for Treatment of Solid Tumors
RekruttererFase 1
- Henry Ford Hospital, Detroit
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
RekruttererFase 1
- Investigative Site #120, Detroit
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
RekruttererFase 1
- Henry Ford Health System, Detroit
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
RekruttererFase 1/2
- Henry Ford Hospital, Detroit
Laser Interstitial Thermal Ablation and Stereotactic Radiosurgery for Patients With Spine Metastases
Rekrutterer
- Henry Ford Hospital, Detroit
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
RekruttererFase 1/2
- Henry Ford Cancer Institute, Detroit
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
RekruttererFase 3
- Henry Ford Health System, Detroit
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
RekruttererFase 1/2
- Karmanos Cancer Institute, Detroit
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
RekruttererFase 1/2
- Karmanos Cancer Institute, Detroit
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
RekruttererFase 1
- Henry Ford Cancer Center, Detroit
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
RekruttererFase 1
- Henry Ford Cancer Institute, Detroit
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
RekruttererFase 1
- Karmanos Cancer Institute, Detroit
A Beta-only IL-2 ImmunoTherapY Study
RekruttererFase 1/2
- Karmanos Cancer Institute, Detroit
Metastatisk kreft-studier i andre byer
- Houston, TX104 studier
- New York City, NY93 studier
- Nashville, TN70 studier
- Boston, MA63 studier
- Los Angeles, CA57 studier
- St. Louis, MO54 studier
- Arlington, VA53 studier
- Philadelphia, PA46 studier
- Chicago, IL45 studier
- San Antonio, TX44 studier
- Washington, DC43 studier
- Dallas, TX42 studier
Andre studier i Detroit
- Ikke-småcellet lungekreft44 studier
- Brystkreft33 studier
- Kreft (alle typer)29 studier
- Kolorektal kreft26 studier
- Eggstokkreft26 studier
- Prostatakreft22 studier
- Endometriekreft21 studier
- Lungekreft20 studier
- Multipelt myelom19 studier
- Mavekreft16 studier
- Plateepitelcancer i hode og hals15 studier
- Akut myelogen leukemi14 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.